A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear. METHODS: In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo. The trial had two phases: a 24-week rapid-dose-escalation phase, followed by a 24-week maintenance phase. The primary end point was histologic improvement (reduction) in MASH with no worsening of fibrosis. Secondary end points included a decrease in liver fat content by at least 30% and biopsy-assessed improvement (reduction) in fibrosis by at least one stage. RESULTS: A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model). A decrease in liver fat content by at least 30% occurred in 63% of the participants in the survodutide 2.4-mg group, 67% of those in the 4.8-mg group, 57% of those in the 6.0-mg group, and 14% of those in the placebo group; improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively. Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%); serious adverse events occurred in 8% with survodutide and 7% with placebo. CONCLUSIONS: Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Self-citationGlucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Cited by
Items 501–537 of 537
Duale und triagonistische Inkretine: Stand und Einfluss auf die MASLD
Kirchhoff, M., & Schattenberg, J. M. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-01015-0
Self-citationCombination pharmacotherapy for MASH: Potential synergistic approaches
Meije, D. A., Holleboom, A. G., & van de Graaf, S. F. J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118492
Reichert, M., Strowitzki, M. J., Tuffs, C., Amati, A., Amin, D., Raj, S., Sprenger, T., Hecker, A., & Schneider, M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2927-4771 · Cited by 1
Neue Therapieansätze bei MASH: Mechanismen und klinisches Potenzial
Barton, A., & Schattenberg, J. M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2894-7716
Self-citationBeyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Defining Weight‐Loss‐Independent Hepatic Effects of Incretin‐Based Therapies
Zhang, M., Liu, H., Hao, Y., & Chen, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71391
Pereira, M. H. K., Kehrwald, L. P., Martini, J. K., Scursoni, S. M., Antunes, I. L., Nunes, M. G., LOUZADA, B. D. B., PEREIRA, L. C., Feron, F. A., Staudt, M. M., et al. (2026) · Editora Pasteur eBooks · doi:10.59290/0422908050
Boutari, C., Charalampidis, K., Sideras, L., Sinakos, E., & Goulis, I. (2026) · Life · doi:10.3390/life16101656
“In a phase 2 randomized trial involving patients with biopsy-confirmed MASH and fibrosis stages F1–F3, survodutide significantly increased MASH resolution and improved hepatic fibrosis, while also reducing liver fat content, body weight, and biomarkers of hepatic inflammation [82].”
Gehlot, D., Bakriwala, S., & Patel, Y. D. (2026) · Annals of the National Academy of Medical Sciences (India) · doi:10.25259/anams_26_2026
Ismaiel, A., & Dumitrascu, D. L. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102146
Endocrine determinants of MASLD: mechanisms and therapeutic targets
Chaturvedi, R., Mathew, A., Pradhan, A., Goyal, M., Sharma, M., Kachroo, V., Agrawal, C., Krishnamurthy, A., Atreja, S. M., & Atreja, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1967494
Buzzi, R. M., & Huber, L. C. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-276106
From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism
Saldívar-Cerón, H. I., Maldonado-Trejo, D., Chavez-Castañeda, Q., Mercado-Guzmán, A. L., León-Barrita, A. D. J., López-García, I. A., Hernández-Solís, A., Ramírez-Mendoza, A. M., Terrazas-Delgado, D. A., Castañeda-Ramírez, A. E., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219654 · Cited by 1
Juárez-Hernández, E., Bautista-Mondragón, C. A., López-Pérez-Alférez, A., Castro‐Narro, G., & López-Méndez, I. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102153
Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ahmad, I., Azmi, S., Albabtain, M. A., Mustafa, M., Kunnathodi, F., Riyasdeen, A., AlWhaiby, B. R., Alharbi, E. M., Arafat, A. A., & Alotaibi, H. F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101281
“…is hepatic and visceral fat mobilization, supported by the Phase II MASH data and by the imaging findings above, rather than incremental total weight loss, and it is accompanied by an additional heart-rate signal and a substantially higher rate of gastrointestinal discontinuation [46,88,123,124].”
InfluentialEmerging pharmacological treatment options for MASLD/MASH
Soto-Campillo, J., García-Rodríguez, M., & Chávez-Tapia, N. C. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.124
Ard, J. D., & Almandoz, J. P. (2026) · Obesity Reviews · doi:10.1111/obr.70228
Argano, C., Maggio, D., Pollicino, C., Cangialosi, V., Manno, S. B., Orlando, V., Monti, M. L., Grutta, A., Torres, A., & Corrao, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784959
Syed‐Abdul, M. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749643
Antidiabetic medications in the pipeline
Efstathiadou, Z. A., Gogakos, A. I., Divaris, E., Kostopoulos, G., & Makri, E. (2026) · HORMONES · doi:10.1007/s42000-026-00780-5
Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report
陈英英, Zhong, X., Guo, X., Xia, Y., Tian, C., & Zheng, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208128
“Additionally, Survodutide, another GLP-1R/GCGR dual agonist, achieved significant histological improvement in a phase II trial involving patients with F2–F3 fibrotic MASH [14].”
Hoffmann, K., Pucek, W. F., Skrzypek, W., Kierzkowski, F., Ratajczak, P., Maggio, V., Rizzo, M., El-Tanani, M., Rabbani, S. A., Bhongade, B. A., et al. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2026.17560
Wu, C., Zheng, Y., Fan, Y., Wang, J., Li, Y., Yuan, Y., Zhao, W., & Tang, Y. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108500
Future directions in obesity pharmacotherapy: Novel targets and pipeline therapies
Mauer, Y., & Isaacs, D. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.003
Caprioli, C. A., Machado, H. T. V., de Alcântara, M. A., Teixeira, A. P., Francischetti, M. V. D., Franco, R. O., Teixeira, P. D. A. A., Lopes, T. B., & de Abreu, J. M. A. (2026) · Brazilian Journal of Health Review · doi:10.34119/bjhrv9n5-131
Pharmacotherapy for MASLD: current evidence and challenges in clinical practice
Pages, L., Rojo, D., Jiménez-Masip, A., Tricarico, E., Mas‐Carrió, E., Aguilar, A., Gómez, N., Molinero, L., & Pericas, J. M. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102477 · Cited by 1
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31
Cheng, P., Lu, C., Lin, C. L., Chiang, C., Yang, H., Kao, H., Wang, C., Chou, T.-J., Chang, M., Hsiao, T.-J., et al. (2026) · Liver International · doi:10.1111/liv.70926
Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective
Pereira, E. N. G. D. S., & Rodrigues, K. L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1981916
Duan, Z.-Q., Wang, H., Sun, C.-H., Wen, R., & Yu, H.-B. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.126681
Sztanek, F. (2026) · Diabetology · doi:10.3390/diabetology7110210
Lauerer, J., Koschker, A., Rau, M., Geier, A., Germer, C., Faßnacht, M., Seyfried, F., & Kollmann, L. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08976-9
Zhu, G., Huang, Y., Huang, Y., & 杨文龙 (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1962068
What Is the Role of GLP-1 Receptor Agonists in the Treatment of MASLD: A Narrative Review
Qari, S. A., Samuel, K., Fallowfield, J. A., Hayes, P. C., Morley, S. D., & Plevris, J. N. (2026) · Livers · doi:10.3390/livers6060109
Seo, Y., & Woo, J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104843
Amatya, R., Benmokadem, Y., Hyun, J. Y., Min, K. A., & Shin, M. C. (2026) · Livers · doi:10.3390/livers6060111
Zhou, D.-J., Yang, J., Sui, G.-Y., Jia, L., Shi, S.-Q., Zhang, C., & Wang, Y. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1950747
Metadata
- Authors
- Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., Hosseini-Tabatabaei, A., Schattenberg, J. M., Noureddin, M., Alkhouri, N., & Younes, R.
- Affiliations
- Inserm (FR)
- From the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); Liverpat and University of Paris (P.B.), and Sorbonne Université, Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris, INSERM Unité Mixte de Recherche Scientifique 1138, Centre de Recherche des Cordeliers (V.R.) — all in Paris; Boehringer Ingelheim, Ingelheim am Rhein (M.F., S.A.H and R.Y.), Saarland University Medical Center, Homburg (J.M.S.), and University of the Saarland, Saarbrücken (J.M.S.) — all in Germany; Covenant Metabolic Specialists, Sarasota, FL (G.W.N.); Houston Methodist Hospital and Houston Research Institute, Houston (M.N.), and the Texas Liver Institute, University of Texas Health San Antonio, San Antonio (E.L. and N.A.) — all in Texas; the University of Turin, Turin, Italy (E.B.); the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, and Newcastle National Institut...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 311-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399439504
- Cited by
- 528
- References
- 28
- Citations by year
- 2026: 212 · 2025: 237 · 2024: 79
- FWCI
- 159.28
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- survodutide, nonalcoholic steatohepatitis, liver fibrosis, glucagon receptor agonist, GLP-1 receptor agonists, liver fat, histologic improvement, dose-response relationship, adverse events, non-alcoholic fatty liver disease, drug safety and efficacy, dose escalation, maintenance phase
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.